Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
Latest Information Update: 13 Dec 2023
At a glance
- Drugs VTP 100 (Primary)
- Indications Influenza A virus H3N2 subtype
- Focus Pharmacodynamics
- Sponsors Barinthus Biotherapeutics; Vaccitech
Most Recent Events
- 31 Jan 2020 According to the Vaccitech media release, the company will continue its obligations under the contract with BARDA to analyse potential immunological correlates associated with protection or risk from disease. The trial was conducted under review by both the FDA and the Belgian Regulatory Authority, FAMHP.
- 31 Jan 2020 Primary endpoint has not been met. (Degree of viral shedding), according to an Vaccitech media release.
- 31 Jan 2020 Results published in the Vaccitech Media Release